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Abstract
HIV-1 escape from surveillance by cytotoxic T lymphocytes (CTL) is thought to cause at least transient weakening of immune
control. However, the CTL response is highly adaptable and the long-term consequences of viral escape are not fully
understood. The objective of this study was to address the question ‘‘to what extent does HIV-1 escape from CTL contribute
to HLA-associated AIDS progression?’’ We combined an analysis of 21 escape events in longitudinally-studied HIV-1 infected
people with a population-level analysis of the functional CTL response in 150 subjects (by IFNg ELISpot) and an analysis of
the HIV-1 sequence database to quantify the contribution of escape to the HLA-associated rate of AIDS progression. We
found that CTL responses restricted by protective HLA class I alleles, which are associated with slow progression to AIDS,
recognised epitopes where escape variants had a weak evolutionary selective advantage (P=0.008) and occurred
infrequently (P=0.017). Epitopes presented by protective HLA class I alleles were more likely to elicit a CTL response
(P=0.001) and less likely to contain sequence variation (P=0.006). A third of between-individual variation in HLA-associated
disease risk was predicted by the selective advantage of escape variants: a doubling in the evolutionary selective advantage
was associated with a decrease in the AIDS-free period of 1.2 yrs. These results contribute to our understanding of what
makes a CTL response protective and why some individuals progress to AIDS more rapidly than others.
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Introduction
HIV-1-infected individuals mount a large, sustained HIV-1-
specific antibody and CD8+ cytotoxic T lymphocyte (CTL) response.
Despite this large immune response, untreated individualsprogressto
AIDS in all but a small minority of cases. There are a number of
hypotheses to explain why the immune response ultimately fails to
control HIV-1 infection including Nef-induced downregulation of
MHC class I, CD8+ cell exhaustion, and destruction of HIV-1-
specific CD4+ cells [1–3]. One hypothesis that continues to evoke
interest is that immune control is lost due to viral escape.
There is clear evidence that HIV-1 variant strains that escape
CTL surveillance (due to impaired MHC binding, TCR recognition
or proteasomal processing) evolve during the course of natural
infection [4–8]. It has been suggested that these escape variants
might contribute to disease progression [9], but the data are
inconclusive. For instance, in four individuals viral escape preceded
anincreaseinviral load,suggesting that escapecancauseanincrease
in viral burden [5,10,11]. However, it is not known whether these
increasesinviral load aremaintained inthe long-termsincetheCTL
responseishighlyadaptable[12]andescapefromoneCTLresponse
can result in an increase in magnitude of other CTL responses to
previously subdominant epitopes [5,10,13]. Nor is HIV-1 escape
always accompanied by a detectable increase in viral load [14–16].
Two large cross-sectional studies showed a relationship between
HLA-associated polymorphisms and high viral load/ low CD4+ T
cell count [17,18]. However, it was not possible to tell whether these
associations were simply because people with a longer duration of
infection or a higher rate of viral production had more chance to
accumulate mutations. Conversely, it has been suggested that the
fitness costs frequently associated with escape mutations may be such
that viral escape has no clinical disadvantage and may even be
advantageous in some cases when the wild type virus is replaced by a
highly attenuated escape variant [19]. Additionally, whilst disease
progression following escape has been described [20], in other cases
individuals have remained healthy for many years after viral escape
[21],and,conversely,diseaseprogression can occurdespite apparent
sequence homogeneity [22]. More recently, work on optimal
epitopes in HIV-infected subjects concluded that protective T cell
responses were actually associated with more frequent viral escape
[23]. The relationship between escape and immune control is also
unclear; HLA class I alleles associated with effective control can
present highly conserved epitopes in structurally constrained regions
(e.g. B*27:Gag p24 131–140) but they can also present epitopes
which are highly susceptible to escape (e.g. B*57:Gag p24 108–117).
Consequently, it is not known whether HIV-1 escape from CTL is
an epiphenomenon that might exacerbate disease progression in a
few atypical cases or whetherit is a significant driving force thatleads
to AIDS in the majority.
The aim of this study was to quantify the contribution of viral
escape from CTL to the HLA-associated rate of progression to
AIDS.
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This study involved the analysis of three datasets: a quantification
of all detailed longitudinal escape events reported in the literature
(21 events in 15 distinct epitope-alleles), analysis of the functional
CTL response in 150 HIV-1 infected individuals and analysis of
sequence variation in clade B HIV-1 sequences from the Los
Alamos National Laboratory (LANL) Sequence Repository.
Evolutionary selective advantage and the rate of
progression to AIDS
Different HLA class I alleles are significantly associated with
different rates of progression to AIDS [24–26]. This has been
quantified as the ‘‘relative hazard’’ of the class I allele [27].
Protective class I alleles, associated with a slow rate of progression
to AIDS, have a low relative hazard; susceptibility alleles,
associated with a rapid rate of progression, have a high relative
hazard. We investigated the relationship between viral escape at
CTL epitopes and the relative hazard of progression to AIDS
(1987 definition) of the presenting class I allele [28].
An escape variant grows out and replaces the wild type strain
because it grows faster than the wild type i.e. it has an evolutionary
selective advantage compared with the wild type. The magnitude
of the selective advantage will depend on the strength of the CTL
response evaded offset by any fitness costs associated with the
escape mutations [29]. The selective advantage of the escape
variant can be estimated by measuring the rate at which the escape
variant grows out and replaces the wild type from the first
appearance of the variant. The selective advantage of the escape
variant was quantified in 21 longitudinally-studied cases of CTL
escape (Table 1,[30]). We found between-individual variation in
the selective advantage of escape variants even at the same
epitope, consistent with variation in the strength of the CTL
response against the same epitope in different people or with
variation in the nature of compensatory mutations between escape
events. Despite this variation, the results show that the selective
advantage of the CTL escape variants was significantly positively
correlated with the HLA-associated rate of progression to AIDS-
1987 (P=0.008, Spearman two-tailed), Fig. 1. That is, protective
HLA class I alleles tended to present epitopes at which the variant
had a weak selective advantage, whereas, susceptibility alleles
tended to present epitopes at which the variant had a large
selective advantage.
As a further test, we compared the selective advantage of escape
variants in epitopes bound by alleles associated with significant
differences in progression to AIDS. We found that variants
escaping CTL responses restricted by the class I alleles B*27 and
B*51, which are significantly associated with a delay in the onset of
AIDS-defining illnesses [27] and protection from AIDS-1993 [31],
had a significantly lower selective advantage than other variants
(P=0.036, Mann-Whitney two-tailed). So, independent of the
definition of AIDS and whether all alleles were considered in rank
Table 1. Escape events.
Reporting paper Epitope location Presenting allele
a Rate of escape Relative Hazard of Presenting Allele
b
(wrt HXB2) (day
21)
1 Jamieson 2003[14] Gag p17 77–85 A*0201 0.006 0.91
2 Kelleher 2001[16] Gag p24 131–140 B*2705 0.002 0.43
3 Kelleher 2001[16] Gag p24 131–140 B*2705 0.001 0.43
4 Goulder 1997[7] Gag p24 131–140 B*27 0.010 0.43
5 Borrow 1997 [4] Env gp160 31–39 B*44 0.048 1.09
6 Milicic 2005 [45] Gag p17 20–28 & 24–31
c A*0301 & B*0801 0.032 0.97
7 Milicic 2005 [45] Gag p17 18–26 A*0301 0.002 0.97
8 Milicic 2005[45] Nef 73–82 A*0301 0.022 0.97
9 Phillips 1991[8] Gag p17 21–35 B*08 20.001 0.97
10 Price 1997 [46] Nef 90–97 B*08 0.049 0.97
11 Koenig 1995[20] Nef 73–82 A*03 0.003 0.97
12 Geels 2003 [6] Env gp41 190–208 A*32 0.005 0.89
13 Geels 2003 [6] Nef 120–128 B*51 0.002 0.85
14 Geels 2003 [6] Pol-RT 128–135 B*51 0.012 0.85
15 Jones 2004 [13] Env gp160 209–217 A*2902 0.072 1.39
16 Jones 2004 [13] Env gp41 73–81 A*1402 0.023 0.7
17 Jones 2004 [13] Tat 24–32 A*2902 0.047 1.39
18 Jones 2004 [13] Env gp160 209–217 A*2902 0.041 1.39
19 Jones 2004 [13] Tat 24–32 A*2902 0.006 1.39
20 Allen 2004 [47] Gag p17 20–28 A*03 0.002 0.97
21 Feeney 2004 [5] Gag p24 131–140 B*27 0.002 0.43
aWhere the presenting Class I allele was serologically determined it has been converted to the equivalent 2-digit genotype using the 2004 HLA Dictionary [48]. Although
this mapping is not in general one-to-one for all the cases where we used it the two digit genotype could be unequivocally determined.
bHLA class I associated relative hazard of progression to AIDS-1987 for the Caucasian population with Class I homozygosity, CCR2 and CCR5 considered as confounding
covariates [28].
cGag 20–28 is presented by A
*0301, Gag 24–31 is presented by B
*0801. A
*03 and B
*08 have the same relative hazard. We have previously studied 19 of these escape
events [30].
doi:10.1371/journal.pone.0003486.t001
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(significantly protective and other) the conclusion was the same:
protective HLA alleles bind epitopes where variants have a low
selective advantage.
We have previously shown that viral escape is significantly more
rapid (higher selective advantage) in primary infection than in
chronic infection [30]; this is also a feature of the dataset studied
here (P=0.003, Mann-Whitney two-tailed) which has consider-
able overlap with the earlier dataset. Consequently, one possible
explanation for the observed association between a large selective
advantage and a high risk of progression to AIDS was that, by
chance sampling, individuals with primary infection were more
likely to bear susceptibility alleles. To investigate this possibility we
grouped the escape events into those occurring in subjects with
chronic infection (N=8) and those occurring in subjects with
primary infection (N=13) and tested for a correlation between the
selective advantage and the relative hazard of the presenting allele
within each group. There was no significant correlation in the
subjects with chronic infection. However, this subject group was
small and had a narrow spread of relative hazards (0.43–0.97),
which makes detection of a significant correlation difficult. In the
subjects with primary infection there was a significant correlation
between the selective advantage and the relative hazard of the
presenting allele (P=0.039 Spearman two-tailed) indicating that
the correlation across the whole dataset was not due to a chance
association between disease stage and HLA type.
Alternatively, analysing the same dataset by epitope location, we
found that escape variants in epitopes located in Gag had a
significantly lower selective advantage than escape variants in
other proteins (P=0.009, Mann-Whitney two-tailed, Fig. 2). This
result did not appear to follow trivially from the relationship
between relative hazard and selective advantage as the relationship
between Gag-targeting and relative hazard was much weaker
(P=0.05, Mann-Whitney two-tailed). Again, this observation is
consistent with the view that protective CTL responses [32,33]
target epitopes where variants have a low selective advantage.
Quantifying the impact of viral escape on progression to AIDS
we found that approximately a third (34%) of the variation in HLA-
associated rate of progression in our subject group could be
explained by variation in the selective advantage. We found that an
Figure 1. The selective advantage of the escape variant predicts the HLA-associated rate of progression to AIDS. The selective
advantage of the escape variant was directly proportional to the relative hazard of the presenting allele (P=0.008, Spearman two-tailed). This
association was still observed if epitopes were grouped by the presenting allele (P=0.007, linear regression weighted by number of points in each
group two-tailed).
doi:10.1371/journal.pone.0003486.g001
Figure 2. Selective advantage of escape variants in Gag and non-Gag epitopes. The selective advantage of escape variants at epitopes in
Gag was significantly lower than the advantage of escape variants at epitopes in non-Gag proteins (P=0.009 Mann-Whitney two-tailed). The dashed
lines depict the median selective advantage in the two groups: 0.02day
21 for non-Gag epitopes, 0.002 day
21 for Gag epitopes. This observation did
not appear to follow trivially from the relationship between relative hazard and selective advantage as the relationship between Gag-targeting and
relative hazard was much weaker (P=0.05, Mann-Whitney two-tailed). However, due to the small number of Gag epitopes studied and the (albeit
weaker) relationship between Gag-targeting and relative hazard this observation should be treated cautiously.
doi:10.1371/journal.pone.0003486.g002
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21 to 0.056 day
21
(equivalent to a decrease in the time to fixation of the variant from
firstappearanceofabout 160 days)wasassociated with a decreasein
the AIDS-free period of about 1.2 years (Methods).
Selective Advantage and the Frequency of Viral Escape
Although variants with a weak selective advantage do replace the
wildtypemoreslowlythan variantswith a strongselective advantage
the time difference is not large and it is hard to reconcile with the
considerable protective effect seen. That is, it is difficult to
understand why a decrease in the time to fixation of only 160 days
could cause a decrease in the AIDS-free period of about 1.2 years.
Onepossibleexplanationisthatescapevariantswithaweakselective
advantage as well as having a longer fixation time from first
appearance will also grow out less frequently. In the absence of a
genetic barrier, population genetics theory [34] predicts that escape
variants with a large selective advantage will grow out more
frequently than those with a small selective advantage (Fig. 3). This
may also partially explain our observation that variants with a large
selective advantage are seen in primary infection. Consequently, we
hypothesise that escape variants with a high selective advantage are
associated with rapid progression to AIDS not so much because they
are fixed morerapidlyfromfirst appearancebut because theyescape
earlier and more frequently leading to greater loss of CTL control.
HIV escape and the absence of CTL responses
If the above hypothesis is correct then we would predict that
epitopes at which variants have a large selective advantage should
Figure 3. Simulation of the Evolution of Escape Variants: the relationship between selective advantage and frequency of escape. In
the absence of a genetic barrier, population genetics theory [34] predicts a positive association between the selective advantage of an escape variant
and the frequency of escape. This is illustrated here by a simulation of the outgrowth of an escape variant with a selective advantage of 0.028 day
21
(A) and a variant with a selective advantage of 0.056 day
21 (B). Black line wild-type virus. Pink line escape variant. Parameter choice: effective
population size=10
3; mutation rate=3610
25 per nucleotide per generation; viral generation time=1 day. Changes to these parameters will change
the absolute waiting time and fixation time but will not alter the positive association between the selective advantage of an escape variant and its
frequency of escape.
doi:10.1371/journal.pone.0003486.g003
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CTL responses in the HIV-1-infected population as a whole. We
tested this prediction by investigating the association between the
selective advantage of variants in the 21 escape events studied and
the functional CTL response to that epitope. The functional CTL
response was quantified by estimating the proportion of individ-
uals (with the presenting allele) who had a detectable CTL
response to the epitope of interest. This was done using a
comprehensive cross-sectional IFNg ELISpot database in which
CD8+ T cells from 150 HIV-1-infected individuals were screened
for responses against 410 overlapping clade B consensus peptides
spanning the entire expressed viral genome [35]. By calculating
the proportion of individuals with the restricting allele who made a
detectable CTL response to each of the epitopes, the relationship
between the selective advantage and the presence or absence of a
CTL response was investigated.
We found a significant negative correlation (Fig. 4) between the
selective advantage of an escape variant and the proportion of
individuals with a detectable CTL response against the wild type
epitope (P=0.017, Spearman two-tailed). That is, wild type
epitopes at which variants had a large selective advantage were less
likely to be recognised (in individuals with the restricting allele)
than epitopes at which variants had a low selective advantage.
As expected- given the positive association between the selective
advantage and the relative hazard, and the negative association
between the selective advantage and the presence of a CTL
response- we found a significant negative association between the
presence of a CTL response and the relative hazard (P=0.001,
Spearman two-tailed). We have replicated this significant negative
association between the presence of a CTL response and relative
hazard in an independent dataset of 84 HIV-1-infected subjects
(P=0.0007 [36]). We suggest that epitopes at which escape
variants have a large selective advantage and epitopes presented
by susceptibility alleles (associated with rapid progression to AIDS)
were less likely to be targeted by CTL because they had
experienced more frequent escape. This observation is consistent
with the hypothesis that rapid, frequent viral escape from CTL is
associated with AIDS progression.
Rate of AIDS progression and virus variation
A further prediction of this hypothesis is that CTL epitopes that
are presented by susceptibility alleles are more likely to contain
amino acid sequence variation than epitopes presented by
protective alleles, due to frequent viral escape in the HIV-1-
infected population. To test this prediction we would ideally have
measured epitope variation only in individuals possessing the HLA
class I allele necessary to present the epitope and thus able to exert
selection pressure. However, this analysis required a large number
(of the order of 100) sequences for every viral protein and HLA
allele necessitating the use of public databases in which the HLA
type of the individual is rarely recorded. We therefore quantified
epitope sequence variation in all individuals regardless of HLA
type. The average Shannon entropy, a measure of amino acid
variation [37], was calculated for each of the epitopes at which
escape was quantified using clade B HIV-1 sequences from the
LANL database (www.hiv.lanl.gov). Env sequences were not
analysed as Envelope is thought to be under dominant selection
by the humoral response. We found a positive correlation between
the variability at an epitope (at which escape had been described)
and the relative hazard of the presenting allele, but this was not
statistically significant (P=0.06 weighted linear regression two-
tailed). However, because sequence is analysed regardless of
subject HLA genotype, the high density of CTL epitopes in many
regions of the genome means that overlap between CTL epitopes
presented by susceptibility alleles and epitopes presented by
protective alleles can occur introducing noise into the dataset. To
reduce noise and to see if our hypothesis was applicable to a
greater range of CTL epitopes (not just the 21 at which CTL
escape had been described) we calculated the Shannon entropy of
all confirmed CTL epitopes from the LANL database defined to
within 11 amino acids that did not overlap with other epitopes
presented by alleles with a different relative hazard. We found a
significant positive correlation between the Shannon entropy of
the CTL epitope and the relative hazard of the presenting allele
(P=0.006 weighted linear regression two-tailed, Fig. 5). Exclusion
of epitopes that could contain drug resistance mutations did not
alter this conclusion (P=0.008 weighted linear regression two-
tailed).
The interpretation that much of the amino acid variation in
CTL epitopes is induced by the selective force of the CTL
response is supported by the observation that the Shannon entropy
was significantly higher at the known anchor residues [38] than at
the non-anchor positions 1 and 6 (P=0.014 Wilcoxon signed rank
two-tailed). Again, this conclusion was not altered when epitopes
Figure 4. Epitopes where escape variants have a weak selective advantage are more likely to be recognised by CTL. In a population of
150 HIV-1-infected individuals it was found that epitopes at which escape variants had a weak selective advantage were more likely to be recognised
by CTL than epitopes where variants had a large selective advantage (P=0.017, Spearman two-tailed). This association was still observed if epitopes
were grouped by the presenting allele (P=0.05, weighted linear regression two-tailed).
doi:10.1371/journal.pone.0003486.g004
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excluded (P=0.03 Wilcoxon signed rank two-tailed).
Discussion
The long-term impact of HIV-1 escape from CTL is poorly
understood and our knowledge of what constitutes a protective
CTL response is incomplete. In this study we estimated the in vivo
evolutionary selective advantage of viral variants that escape the
CTL response and related these estimates to the degree of
protection conferred by the targeting CTL response. This analysis
suggested that viral escape from the CTL response is a significant
determinant of the HLA-associated rate of AIDS progression. We
corroborated this work by analysing an IFNg ELISpot and an
HIV-1 sequence database using two independent methods. The
results were consistent with the conclusions that (1) viral escape is a
significant determinant of the HLA-associated rate of AIDS
progression and (2) protective CTL responses target epitopes
where escape variants have a weak selective advantage and escape
is thus less frequent (Fig. 6).
It is important to appreciate that we have quantified the
relationship between escape and the HLA-associated rate of AIDS
progression, not the total rate of AIDS progression. The HLA-
associated rate of progression is a fraction of the total rate and is
more likely to be CTL-dependent. Consequently the observation
that approximately 30% of HLA-associated variation can be
explained by escape does not mean that 30% of the overall rate of
progression can be explained by escape.
It is unclear why the selective advantage of escape variants
varies. The selective advantage of an escape variant compared to
the wild type is determined by two main factors: the strength of the
CTL response evaded and the fitness cost of the escape mutations.
Consequently, the low selective advantage of escape variants in
epitopes targeted by protective CTL responses could either be due
to protective CTL responses being inherently weak or due to high
fitness costs of mutations in these epitopes. If protective CTL
responses are inherently weaker than susceptibility responses that
would suggest that CTL play an immunopathological role in
AIDS development. Whilst there is evidence from comparative
studies of SIV-infected rhesus macaques and sooty mangabeys that
strong immune responses may be detrimental this appears to apply
mainly to bystander CD4+ cell responses rather than HIV-1-
specific CD8+ cell responses [39,40]. We therefore currently
favour the alternative explanation that protective CTL responses
tend to target regions of the viral genome where mutations carry a
heavy fitness cost. This is consistent with work showing that CTL
targeting Gag, which is relatively intolerant of mutations, are
associated with lower viral loads [32,33]. Interestingly, in our
dataset the selective advantage of escape variants in Gag was
indeed significantly lower than the selective advantage of escape
Figure 5. HLA Class I alleles associated with rapid progression present more variable CTL epitopes. The Shannon entropy was
calculated using clade B sequences from the LANL database. The average Shannon entropy of an epitope was significantly correlated with relative
hazard (P=0.006, weighed linear regression two-tailed). This association was still significant if either of the two points that apparently contribute
strongly to the association ([0.48, 1.87] or [0.75, 1.25]) were removed from the dataset (P,0.0005 and P=0.021 respectively).
doi:10.1371/journal.pone.0003486.g005
Figure 6. Results summary and hypothesised unifying model.
We suggest that some HLA class I molecules like B*51 and B*27 tend to
bind epitopes where escape mutations carry a heavy fitness cost.
Consequently the selective advantage of escape variants at these
epitopes is low, this is manifest as a relatively slow rate of escape
(P=0.008). Due to the low selective advantage of these escape variants,
escape is less frequent than in epitopes presented by other alleles
(P=0.017). Infrequency of escape at epitopes bound by protective
alleles is manifest both as decreased amino acid sequence variation
(P=0.006) and an increased likelihood of a detectable CTL response
against the wild type epitope (P=0.001, P=0.0007). This in turn leads to
better maintenance of CTL control and slower progression to AIDS. The
protective effect of HLA alleles like B*27 and B*51 due to the low
selective advantage of escape variants at the epitopes they present may
be compounded because even when escape (infrequently) occurs the
resulting variant will be heavily crippled compared to escape variants at
epitopes presented by other alleles. Importantly, as HLA genotype
clearly cannot change with disease status; selective advantage is
unlikely to be caused by viral load (for theoretical reasons and in
agreement with the data) and because frequency of escape cannot
cause selective advantage it is much easier to infer the direction of
causality from this group of three observations than if we had simply
seen an association between frequency of escape and HLA associated
rate of progression. The arrows indicate the suggested direction of
causality.
doi:10.1371/journal.pone.0003486.g006
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with caution because of the very small number of Gag epitopes
studied but the observation is consistent with the idea that
protective CTL responses recognise epitopes where escape
variants have a weak selective advantage.
It is interesting and counter-intuitive that CTL responses restricted
by protective alleles, that might be expected to be stronger than
average, actually mediate less amino acid variation than potentially
weaker susceptibility responses. It would appear that strong CTL
responses – those that kill infected cells rapidly and exert a large
selectionpressure-arenot necessarilythemostprotective.Clearlythis
does not rule out the possibility that protective CTL responses are
strong but that the balance between strength and epitopes targeted is
such that long-termprotection from AIDS appearsto be more closely
related to prevention of escape than strength per se, giving rise to a
positive rather than negative association between selective advantage
and relative hazard (Fig. 1). This conclusion has important
implications for vaccine design. Many of the HIV-1 vaccine strategies
currently being pursued utilising heterologous prime-boost protocols
which give the most promising short-term viral control, are also the
strategies that appear to induce the most rapidviral escape from CTL
[41]. That is, these vaccines appear to induce strong rather than long-
term protective responses. These results emphasise the importance of
preventing escape, perhaps even at the expense of short-term control.
As well as quantifying the contribution of viral escape to AIDS
progression these results help to explain why some HLA class I
alleles offer more protection than others. They show that the
degree of HLA protection associated with different alleles is related
to the selective advantage of variants in the bound epitopes. This
supports the view that a significant proportion of class I protective
effects are due to differences in the CTL response rather than
effects like NK licensing or folding abnormalities.
One possible explanation for the observed association between a
large selective advantage and susceptibility HLA genes is that
individuals with susceptibility genes may have a high viral load and
thus a high level of viral replication which could facilitate rapid viral
escape. However, this explanation is unlikely because the selective
advantage is not dependent on the mutation rate but on the
difference in growth rate between the wild type and the variant
strain and there is no reason why this difference should be positively
dependent on viral load. Indeed, it has recently been argued that, if
anything a negative association between viral replication and
difference in growth rate might be expected [42]. Our position, that
the observed association between selective advantage and relative
hazard cannot be explained by differences in viral load, is supported
by the data which show no significant association between the
selective advantage and viral load prior to escape.
Two previous studies have reported a positive association between
high viral load/ low CD4+ cell count and HLA-associated
polymorphisms [17,18]. However, in these studies it was not possible
to tell whether a high viral load/ long duration of infection caused a
high number of polymorphisms or whether the polymorphisms
caused clinical decline [17]. Here, by assessing evolutionary selective
advantage from longitudinal data, which we demonstrated was
independent of viral load, rather than cross-sectional mutation
frequency we were able to ascertain the direction of causality: viral
escape from CTL appears to contribute to clinical decline.
This longitudinal study and the two cross-sectional studies
discussed above find a positive association between disease
progression and virus variation [17,18]. However, a third cross-
sectional study shows a negative association with protective CTL
responses being associated with frequent viral escape [23]. The
reason for this discrepancy is unclear but one possible explanation is
that the latter study measured selection pressure by measuring the
frequency of variants in optimal epitopes in subjects with the
presenting allele compared with subjects lacking the presenting
allele arguing that a high frequency of variants in subjects without
thepresentingallelewas evidenceofa lowfitnesscost.However, this
analysis did not take into account variation in HLA frequency. In
particular transmitted virus is more likely to be shaped by common
alleles than rare alleles and thus variants that escape recognition by
CTL responses restricted by common alleles would be expected to
be more frequent in the population. That is, the reported result [23]
may simply reflect rare allele advantage [43] rather than indicate
that protective CTL responses drive escape frequently.
This study is limited by the relatively small number (21) of cases
of detailed longitudinal escape in the literature. However, both
associations utilising these 21 events (selective advantage-relative
hazard and selective advantage-frequency of CTL targeting) were
significant (P=0.008, P=0.017) and the latter is also predicted by
classical population genetics theory. Furthermore, the association
between frequency of escape and relative hazard predicted by our
hypothesis, as well as being confirmed in a large (N=150) cohort
(P=0.001), was also confirmed using an alternative method in two
large independent cohorts (P=0.006, P=0.0007) using two
surrogate markers of the frequency of escape. All the results are
consistent with each other and support the hypothesis (Fig. 6). We
hope that this work provides the rationale for a much larger
longitudinal study of HLA-diverse HIV-1-infected patients.
These results contribute to our understanding of why HIV-1-
infected individuals differ in their rate of progression to disease and
of what constitutes a protective CTL response and thus have direct
implications for vaccine design. Most importantly they suggest that
viral escape from CTL is a determinant of the rate of HLA-
associated progression to AIDS.
Methods
Quantification of the selective advantage of an escape
variant
The selective advantage of an escape variant compared with the
wild type was estimated from longitudinal viral sequence data
showing the replacement of the wild type by the escape variant
[30]. The selective advantage of an escape variant compared to
the wild type is equal to the difference in growth rates between the
escape variant and the wild type and is manifest as the rate at
which the escape variant replaces the wild type. If cells
productively infected with wild type virus grow at a rate r and
cells productively infected with the escape variant grow at a rate
k+r, then the selective advantage of the escape variant is k and the
dynamics of the two cell populations will be given by
dy
dt ~ry wild type
dx
dt ~rxzkx variant:
ð1Þ
Ifp(t) istheproportionofviralsequencesthat have escapemutations
in the epitope of interest at time t then solving (1) we have
pt ðÞ ~
xt ðÞ
yt ðÞ zxt ðÞ
~
1
ge{ktz1
ð2Þ
where g=y(0)/x(0).
This model has been derived in population genetic theory to
describe the fixation trajectory of an advantageous mutation in a
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escape data using nonlinear least squares regression (Levenberg-
Marquardt method) and the selective advantage of the variant k
estimated. A selective advantage of k per day is roughly equivalent
to a time to fixation (from initial appearance of the escape variant)
of about 9/k i.e. a variant with a selective advantage of 0.01 day
21
takes approximately 900 days to replace the wild type population.
HIV-1 Escape Datasets
To quantify the selective advantage of HIV-1 escape variants it
was necessary to have longitudinal data with two or more time
points where the frequency of the escape variant was neither zero
nor one. There are twenty-three such data sets in the literature.
For two of these datasets the presenting HLA class I allele was
unknown and so these two datasets were excluded from further
analysis. Information on the escape events studied is given in
Table 1. We have previously studied 19 of these 21 cases [30].
Time to progression
The change in median time from seroconversion to AIDS-1987
associated with a change in selective advantage (Dk) was estimated
using the relationship between the selective advantage and relative
hazard (Fig. 1) and the relationship between relative hazard and
time to AIDS [31]. From regression in Fig. 1 rh=8.53k+0.76 so a
change in selective advantage of Dk is associated with a change in
relative hazard of 8.53Dk. Analysis of Kaplan Meier curves for
progression to AIDS-1987 [31] indicate that there is a roughly
linear relationship between the probability of survival for t years
after seroconversion (tp) and the time since seroconversion
(tp=mt+c; with m=20.06 and c=1 [31,44]). Therefore the
baseline hazard function mt~{ 1
tp
d
dt tp~ {m
mtzc. The median time
to progression, T, associated with the baseline hazard is the time
for 50% of the cohort to develop AIDS i.e. the solution of
0:5~exp {
Ð T
0
ms ds
"#
; which is T=20.5/m. If the relative hazard
is increased by 8.53Dk then the elevated hazard function is
m’t~mt 1z8:53Dk ðÞ and the correspondingly reduced median
time to progression is T’~ 0:5 1z8:53Dk ðÞ {1
{1
m . For m=20.06 the
baseline time to progression is 8.3 years and for Dk=0.028day
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the reduced time to progression is 7.11 years, a difference of 1.2
years. This relationship between the relative hazard and the time
to progression was also used to estimate the time to AIDS listed in
Fig. 1.
Absence/ presence of CTL responses
To ascertain the relationship between the selective advantage of
escape variants at an epitope and the functional CTL response to
that epitope a comprehensive, published IFNg ELISpot database
was analysed [35]. This database contains the results of screening
CD8+ T cells from 150 HIV-1-infected individuals for IFNg
responses to 410 overlapping clade B consensus sequence peptides
spanning all HIV-1 proteins. For each of the 21 CTL epitopes at
which we quantified the selective advantage we calculated the
proportion of individuals bearing the presenting allele who had a
detectable CTL response to the peptide wholly containing the
CTL epitope. If the epitope was wholly contained within more
than one peptide then the mean proportion was used.
Measure of amino acid variation: Shannon entropy
The Shannon entropy is a measure of amino acid variation at a
position [37], it takes into account both the variety and frequency
of amino acids observed at that position. The Shannon entropy
was calculated for each residue of HIV-1 clade B protein
alignments, using only complete proteins and only one sequence
per patient. Sequences, which were restricted to subjects from
Europe and North America to enrich for Caucasians, were taken
from the LANL HIV sequence database which contains all
publicly available HIV sequences. To estimate the Shannon
entropy of an epitope the mean entropy of all positions in the
epitope was calculated. We investigated the impact of sequence
Table 2. CTL epitopes.
Epitope Location
a Presenting allele
b
IEIKDTKEAL Gag p17 92–101 B*40
EVKDTKEAL Gag p17 93–101 B*08
NSSKVSQNY Gag p17 124–132 B*35
NYPIVQNL Gag p17–p24 131–6 A*24
VLAEAMSQV Gag p24–p2 A*02
EEMNLPGRW Protease 34–42 B*44
ALVEICTEMEK RT 33–43 A*03
EKEGKISKI RT 42–50 B*51
KLVDFRELNK RT 73–82 A*03
TAFTIPSI RT 128–135 B*51
DLEIGQHRTK RT 192–201 A*03
QIYQEPFKNLK RT 340–350 A*11
RMRGAHTNDVK RT 356–366 A*03
ALQDSGLEV RT 485–493 A*02
QPDKSESELV RT 509–518 B*07
YLAWVPAHK RT 532–540 B*07
LPPVVAKEI Integrase 28–36 B*51
LLWKGEGAV Integrase 241–249 A*02
RKAKIIRDY Integrase 263–271 B*15
RIRTWKSLVK Vif 17–26 A*03
HMYISKKAK Vif 28–36 A*03
KLTEDRWNK Vif 168–176 A*03
AIIRILQQL Vpr 59–67 A*02
CCFHCQVC Tat 30–37 Cw*12
ISERILSTY Rev 55–63 A*01
SAEPVPLQL Rev 67–75 Cw*05
LFCASDAKAY Env gp160 52–61 A*24
KLTPLCVTL Env gp160 121–129 A*02
YRLINCNTSV Env gp160 191–200 A*02
LPCRIKQII Env gp160 416–424 B*51
RLVNGSLAL Env gp160 747–755 A*02
QELKNSAVSL Env gp160 805–814 B*40
SLLNATDIAV Env gp160 813–822 A*02
RVIEVLQRA Env gp160 828–836 A*02
RAYRAILHI Env gp160 835–843 B*51
QGLERALL Env gp160 849–856 B*08
KEKGGLEGL Nef 92–100 B*40
TPGPGVRY Nef 128–135 B*07
aEpitope location given with respect to HXB2.
bWhere the presenting Class I allele was serologically determined it has been
converted to the equivalent 2-digit genotype using the 2004 HLA Dictionary .
If the two digit genotype could not be unequivocally determined the epitope
was removed from the list.
doi:10.1371/journal.pone.0003486.t002
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a set of 499 sequences. This analysis showed that entropy stabilised
and remained constant for number of sequences .60.
To exclude the possibility of drug resistance mutations
impacting on the entropy calculations, epitopes containing amino
acid positions known to acquire mutations causing high,
intermediate or low level resistance to RT and protease inhibitors
(Stanford University Drug Resistance database) were removed
from the list of epitopes and all the calculations were repeated.
Anchor residues for each HLA allele studied were determined
from [38] (analysis was repeated simply assuming the 2
nd and C-
terminus positions were the anchor residues for every allele and
the conclusions were unaltered). Non-anchor residues were
represented by the 1
st and 6
th position (analysis was repeated
using the 4
th and 7
th position as non-anchor residues and the
conclusions were unaltered. The 3
rd,5
th and 8
th positions were
putative anchor residues for some of the alleles studied and could
therefore not be confidently considered as non-anchor residues).
CTL epitopes
When we widened the analysis beyond the 21 escape events at
defined CTL epitopes in the literature, epitopes were taken from
the LANL HIV immunology database. All epitopes that were
confirmed (appeared twice or more in the database), for which the
presenting allele was known (either genotyped or in the case of
serotyping having an equivalent unique 2-digit genotype) and
determined to within 11 amino acids were selected. All replicates
were removed (the same epitope but with a different presenting
allele was not considered a replicate). We wished to calculate the
Shannon entropy for each CTL epitope to investigate the
relationship between the relative hazard of the presenting allele
and the amount of sequence variation. Ideally we would have
estimated the entropy of say an A2-presented epitope only in A2+
subjects. However, since the vast majority of the HIV-1 sequences
used for our entropy calculations were from subjects of unknown
HLA type this was not possible. Instead, to reduce the noise that
looking at say A2-presented epitopes in both A2+ and A2- subjects
will introduce, we removed all epitopes that were presented by
infrequent alleles (frequency,5% in the Caucasian population)
and further removed all epitopes that overlapped by more than 1/
3 with another epitope where the relative hazard of the presenting
allele differed by more than 10%. This left a total of 38 epitopes
(Table 2). For the purposes of Shannon entropy calculations
epitopes in Env were removed as the Shannon entropy is known to
inadequately reflect antigenic variation in Env and because Env is
under dominant selection by the humoral response.
Simulation of the time to fixation
The illustrative simulation (Fig. 3) was implemented in Maple
(Waterloo Maple Inc.) using an effective population size of 10
3,a
mutation rate of 3610
25 per nucleotide per generation and a
generation time of 1 day. 3 possible nucleotide mutations were
considered, one of which had a selective advantage compared to
the wild type, the other two had the same fitness as the wild type.
Changes to these parameters will not alter the positive association
between the selective advantage of an escape variant and its
frequency of escape.
Statistics
All statistical tests used were non-parametric except when we
needed to perform a weighted test. In the latter case linear
regression with the data weighted either by the number of subjects
in the group or by the number of sequences contributing to the
entropy calculation was used. Whenever weighted regression was
used we additionally checked that the non-parametric Spearman
rank test yielded the same conclusion. All tests were suitable for the
sample size. All P-values reported are two-tailed.
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